GlassScriptPhysician profile
Charles C Tuen
NPI 1114919412
$3,062.12
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,026 · 2021: $951 · 2022: $27.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $446.30 | 2019-2021 | |
| Emd Serono, INC. | $335.58 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $288.77 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $247.16 | 2019-2021 | |
| Biogen, INC. | $216.95 | 2019-2021 | |
| Abbvie INC. | $176.29 | 2021 | |
| Ucb, INC. | $158.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $132.51 | 2019-2021 | |
| Genentech USA, INC. | $125.61 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $99.94 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $95.93 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $95.43 | 2019-2020 | |
| Pfizer INC. | $82.12 | 2019-2022 | |
| Allergan, INC. | $75.51 | 2019-2020 | |
| Sk Life Science, INC. | $65.14 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $63.90 | 2021 | |
| Kyowa Kirin, INC. | $57.10 | 2020-2021 | |
| Lilly USA, LLC | $49.51 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $49.33 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $48.75 | 2020-2021 | |
| Amgen INC. | $43.15 | 2021 | |
| Acorda Therapeutics, INC | $22.80 | 2019 | |
| Celgene Corporation | $15.65 | 2020 | |
| Acadia Pharmaceuticals INC | $15.34 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.14 | 2019 | |
| Aquestive Therapeutics, INC. | $14.56 | 2021 | |
| Mdd US Operations, LLC | $13.13 | 2019 | |
| Neurelis, INC. | $11.70 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Tuen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.